Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

27.02.2018 | Onkologie | editorial

Revival of anti-angiogenic therapies in cancer

News from an old therapeutic concept—part 2

verfasst von: Andreas Pircher, MD PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Auszug

Referring to the last issue presenting state of the art reviews [1] on the use of anti-angiogenic drugs in colorectal [2], urological [3, 4] and breast cancer [5] as well as in angiosarcomas [6], the present issue extends the topic to additional angiogenesis-dependent malignancies. Hereby, ovarian cancer and non-small cell lung cancer (NSCLC) represent two highly vascularized tumor entities where anti-angiogenic therapies form a robust backbone for the treatment of advanced stage disease mostly in combination with chemotherapy or newer therapeutic therapies. …
Nächster Artikel Uro-oncology 2018: new horizons, new treatment options, improved patient outcomes
Literatur
1.
Pircher A. Revival of anti-angiogenic therapies in cancer—news on an old therapeutic concept. Memo. 2017;10(4):185–6.CrossRef
2.
Stragier E, Prenen H. Antiangiogenic therapies in colorectal cancer. Memo. 2017;10(4):213–7.CrossRef
3.
4.
5.
6.
7.
8.
9.
Metadaten
Titel
Revival of anti-angiogenic therapies in cancer
News from an old therapeutic concept—part 2
verfasst von
Andreas Pircher, MD PhD
Publikationsdatum
27.02.2018
Verlag
Springer Vienna
Schlagwort
Onkologie
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0394-0

Weitere Artikel der Ausgabe 1/2018

Practice-changing developments in early use of chemohormonal therapy in metastatic prostate cancer

  • short review

Uro-oncology 2018: new horizons, new treatments, better outcomes

My burning issues in TKI therapy and treatment-free remission in CML

  • editorial

Short overview on the current standard of treatment in newly diagnosed multiple myeloma

  • Open Access
  • short review

ESMO 2017—my personal highlights

  • Open Access
  • comment

Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity

  • Open Access
  • case report